Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

Diabetes, Obesity & Metabolism
Kohei KakuR Matsuno

Abstract

To assess the efficacy and safety of fasiglifam 25 and 50 mg in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. This phase III, double-blind, placebo-controlled, multicentre study included 192 patients randomized to once-daily treatment with fasiglifam 25 mg (n = 63) or 50 mg (n = 62) or placebo (n = 67) for 24 weeks. The primary efficacy endpoint was the change from baseline in glycated haemoglobin (HbA1c) at week 24. At week 24, both fasiglifam groups had significantly reduced HbA1c levels compared with the placebo group (p < 0.0001). The least squares mean change from baseline in HbA1c was 0.16% with placebo, -0.57% with fasiglifam 25 mg and -0.83% with fasiglifam 50 mg. The percentage of patients who achieved an HbA1c target of <6.9% at week 24 was also significantly higher (p < 0.05) for fasiglifam 25 mg (30.2%) and 50 mg (54.8%) compared with placebo (13.8%). Fasiglifam significantly reduced fasting plasma glucose levels at all assessment points, starting from week 2. The incidence and types of treatment-emergent adverse events in each fasiglifam group were similar to those in the placebo group, and hypoglycaemia was reported in 1 patient receiving fasiglifam 50 mg. There were no clini...Continue Reading

References

Sep 1, 1987·Diabetes Care·D J CoxJ Butterfield
May 19, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·D R MatthewsR C Turner
Jul 9, 1999·Diabetes/metabolism Research and Reviews·P E Cryer
Feb 8, 2003·Science·James O HillJohn C Peters
Nov 10, 2009·Diabetes Research and Clinical Practice·J E ShawP Z Zimmet
Feb 9, 2012·Annals of Internal Medicine·Amir QaseemUNKNOWN Clinical Guidelines Committee of the American College of Physicians
Mar 1, 2012·Lancet·Clifford J Bailey
Jun 4, 2013·Expert Opinion on Emerging Drugs·Avivit Cahn, Itamar Raz
Feb 20, 2012·Journal of Diabetes Investigation·Atsunori KashiwagiUNKNOWN Committee on the Standardization of Diabetes Mellitus‐Related Laboratory Testing of Japan Diabetes Society
Sep 9, 2010·ACS Medicinal Chemistry Letters·Nobuyuki NegoroYu Momose

❮ Previous
Next ❯

Citations

Feb 24, 2016·Journal of Enzyme Inhibition and Medicinal Chemistry·Mikhail KrasavinSergey Zozulya
Nov 19, 2015·Pharmaceutical Patent Analyst·Rosa FormicolaMariangela Sodano
Jun 15, 2016·Chemical Reviews·Graeme MilliganBrian D Hudson
Feb 3, 2016·British Journal of Pharmacology·Tony NgoNicola J Smith
Oct 19, 2016·International Journal of Molecular Sciences·Volker M Lauschke, Magnus Ingelman-Sundberg
Oct 27, 2016·Journal of Enzyme Inhibition and Medicinal Chemistry·Mikhail KrasavinSergey Zozulya
Feb 17, 2017·Toxicological Sciences : an Official Journal of the Society of Toxicology·Monicah A OtienoHeng-Keang Lim
Feb 3, 2018·British Journal of Pharmacology·Kyle W SloopFrancis S Willard
Mar 21, 2018·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Akifumi KogameYoshihiko Tagawa
Jun 7, 2017·Journal of Lipid Research·Santhosh SatapatiJin Shang
Mar 2, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·John F MarcinakNeila Smith
Sep 17, 2018·Nucleic Acids Research·Ying LiuMartin Fussenegger
Feb 16, 2019·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Akifumi KogameLeslie Z Benet
Jun 29, 2017·Pharmacological Reviews·Anna CooperAndrea J Vernall
Nov 3, 2016·Molecular Pharmacology·J M Houthuijzen
Sep 6, 2019·Physiological Reviews·Ikuo KimuraMiki Igarashi
Nov 7, 2019·Science Translational Medicine·Kyung-Jin JangGeraldine A Hamilton
Aug 31, 2018·Current Drug Discovery Technologies·Krishna A Gajjar, Anuradha K Gajjar
Oct 28, 2017·Nature Reviews. Drug Discovery·Alexander S HauserDavid E Gloriam
Mar 24, 2018·Chemical Science·James Allen FrankDirk Trauner

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception
pregnancy test

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.